A Study on Assessment of Adverse Drug Reaction Monitoring In Cardiac Patients in a Tertiary Care Hospital
Abstract
Cardiovascular disease describes coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic and congenital heart disease and venous thromboembolism. Collectively, cardiovascular disease is responsible for 17.9 million deaths per year globally 31% of all deaths, within which Ischaemic Heart disease accounts for the majority of mortality. The present study aimed to assess adverse drug reaction monitoring in cardiac patients in a tertiary care hospital. 31-40 years age patients were 56 (26.66%), 41-50 years age patients were more 56 (26.66%) as compared to other age groups. Calcium channel blockers patients were more 56 (26.66%), as compared to Beta blockers patients were 44 (20.95%), Nitrates patients were 54 (26.71%), Alpha blockers patients were 56 (26.66%), Carbonic anhydrase inhibitors patients were 56 (26.66%). Central nervous system affected patients were more (68%), as compared to Respiratory system affected patients were (56%), Gastrointestinal system affected patients were (39%), Cardiovascular system affected patients were (47%), Musculoskeletal system affected patients were (68%). Adverse drug reactions potential for a particular cardiovascular drug varies with the individual, the disease being treated, and the extent of exposure to other drugs. Knowledge of this complex interplay between patient, drug, and disease is a critical component of safe and effective cardiovascular disease management. The risk of Adverse drug reactions increased with the number of drugs in the prescription. Most of the Adverse drug reactions were mild in severity and were not preventable. The timely therapy adjustment can helps to optimize pharmacotherapy and reduce the severity of these reactions.
Keywords:
Cardiovascular disease, Venous thromboembolism, Peripheral arterial disease, Prescription, cerebrovascular disease, Adverse drug reactionsDOI
https://doi.org/10.70604/learnint.v2i1.63References
1. Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am CollCardiol 2017; 70: 1–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
2. Rabar S, Harker M, O'Flynn N, et al. ; Guideline Development Group. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ 2014; 349: g4356. [DOI] [PubMed] [Google Scholar]
3. Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, et al. European Heart Network. European Cardiovascular Disease Statistics 2017. Brussels: European Heart Network.
4. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–952. [DOI] [PubMed] [Google Scholar]
5. Conroy RM, Pyörälä K, Fitzgerald A, et al. ; SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003. [DOI] [PubMed] [Google Scholar]
6. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am CollCardiol 2019; 74: 1376–1414. [DOI] [PMC free article] [PubMed] [Google Scholar]
7. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am CollCardiol 2014; 63: 2935–2959. [DOI] [PMC free article] [PubMed] [Google Scholar]
8. Kengne AP, Patel A, Marre M, et al. ; ADVANCE Collaborative Group. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J CardiovascPrevRehabil 2011; 18: 393–398. [DOI] [PubMed] [Google Scholar]
9. Stam-Slob MC, Visseren FL, Jukema JW, et al. Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. Clin Res Cardiol 2017; 106: 58–68. [DOI] [PMC free article] [PubMed] [Google Scholar]
10. Lavie C, O'Keefe J, Church T, et al. The role of physical fitness in cardiovascular disease prevention. The Medical Roundtable General Medicine Edition 2020.
11. Liu Y, Lee DC, Li Y, et al. Associations of resistance exercise with cardiovascular disease morbidity and mortality. Med Sci Sports Exerc 2019; 51: 499–508. [DOI] [PMC free article] [PubMed] [Google Scholar]
12. Eijsvogels TM, Molossi S, Lee D, et al. Exercise at the extremes: the amount of exercise to reduce cardiovascular events. J Am CollCardiol 2016; 67: 316–329. [DOI] [PubMed] [Google Scholar]
13. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am CollCardiol 2014; 63: 2960–2984. [DOI] [PubMed] [Google Scholar]
14. De Souza RJ, Mente A, Maroleanu A, et al. Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ 2015; 351: h3978. [DOI] [PMC free article] [PubMed] [Google Scholar]
15. Song M, Fung TT, Hu FB, et al. Association of animal and plant protein intake with all-cause and cause-specific mortality. JAMA Intern Med 2016; 176: 1453–1463. [DOI] [PMC free article] [PubMed] [Google Scholar]
16. Wing RR, Lang W, Wadden TA, et al. ; the Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011; 34: 1481–1486. [DOI] [PMC free article] [PubMed] [Google Scholar]
17. Brown JD, Buscemi J, Milsom V, et al. Effects on cardiovascular risk factors of weight losses limited to 5–10%. TranslBehav Med 2016; 6: 339–346. [DOI] [PMC free article] [PubMed] [Google Scholar]
18. Van Dijk S, Takken T, Prinsen E, et al. Different anthropometric adiposity measures and their association with cardiovascular disease risk factors: a meta-analysis. Neth Heart J 2012; 20: 208–218. [DOI] [PMC free article] [PubMed] [Google Scholar]
19. Law MR, Wald NJ. Environmental tobacco smoke and ischemic heart disease. ProgCardiovasc Dis 2003; 46: 31–38. [DOI] [PubMed] [Google Scholar]
20. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016; 387: 2507–2520. [DOI] [PubMed] [Google Scholar]
21. Hartmann-Boyce J, Hong B, Livingstone‐Banks J, et al. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane DatabSyst Rev 2019; 6: 1465–1858. [DOI] [PMC free article] [PubMed] [Google Scholar]
22. Shields PG, Berman M, Brasky TM, et al. A review of pulmonary toxicity of electronic cigarettes in the context of smoking: a focus on inflammation. Cancer Epidemiol Biomarkers Prev 2017; 26: 1175–1191. [DOI] [PMC free article] [PubMed] [Google Scholar]
23. Hom S, Chen L, Wang T, et al. Platelet activation, adhesion, inflammation, and aggregation potential are altered in the presence of electronic cigarette extracts of variable nicotine concentrations. Platelets 2016; 27: 694–702. [DOI] [PubMed] [Google Scholar]
24. Nocella C, Biondi-Zoccai G, Sciarretta S, et al. Impact of tobacco versus electronic cigarette smoking on platelet function. Am J Cardiol 2018; 122: 1477–1481. [DOI] [PubMed] [Google Scholar]
25. Moheimani RS, Bhetraratana M, Peters KM, et al. Sympathomimetic effects of acute E‐cigarette use: role of nicotine and non‐nicotine constituents. JAHA 2017; 6: e006579. [DOI] [PMC free article] [PubMed] [Google Scholar]
26. Bell S, Daskalopoulou M, Rapsomaniki E, et al. Association between clinically recorded alcohol consumption and initial presentation of 12 cardiovascular diseases: population based cohort study using linked health records. Bmj 2017; 356: j909. [DOI] [PMC free article] [PubMed] [Google Scholar]
27. Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus: the ASCEND study collaborative group. J VascSurg 2019; 69: 305. [DOI] [PubMed] [Google Scholar]
28. Stewart J, Manmathan G, Wilkinson P. Primary prevention of cardiovascular disease: a review of contemporary guidance and literature. JRSM Cardiovasc Dis 2017; 6: 2048004016687211. [DOI] [PMC free article] [PubMed] [Google Scholar]
29. Ramos R, Comas-Cufi M, Marti-Lluch R, et al. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. Bmj 2018; 362: k3359. [DOI] [PMC free article] [PubMed] [Google Scholar]
30. Kirkman MS, Mahmud H, Korytkowski MT. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes mellitus. EndocrinolMetabClin North Am 2018; 47: 81–96. [DOI] [PubMed] [Google Scholar]
Published
Abstract Display: 50 
PDF Downloads: 20 How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Deprecated: json_decode(): Passing null to parameter #1 ($json) of type string is deprecated in /home/lapinjournals/domains/lapinjournals.com/public_html/plugins/generic/citations/CitationsPlugin.php on line 68
.